Phytochemicals from cannabis exhibit therapeutic promise in impeding the progression of neurodegenerative conditions. Specifically, CBD and cannflavins can hinder enzymes integral to the synthesis of arachidonic acid from the endocannabinoid 2-arachidonoylglycerol which acts as a natural suppressor of neuroinflammation, thereby alleviating neuropathologies in models of neurodegenerative disorders. Encouraged by the favorable impact of cannflavins in an initial screening involving mutant Caenorhabditis elegans models for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, our research group opted to further investigate the potential effects of both cannflavins and cannabinoids in alleviating neuro-motor ailments. This led to an examination using a Zebrafish model exhibiting a broad spectrum of ALS-like symptoms induced by the neurotoxin β-N-methylamino-L-alanine (BMAA). The restoration of impaired motility in zebrafish larvae due to BMAA-induced neuronal dysfunction by the tested compounds suggests a compelling rationale for potentially extending their evaluation in clinical trials to a wider range of ALS patients and validates this screening tool for the discovery of novel neurodegeneration therapeutics.